Novavax Inc vs WD 40 Company — how do they compare? Novavax Inc trades at $7.92 (market cap $1.31B), while WD 40 Company trades at $231.66 (market cap $3.13B). The key difference: WD 40 Company is far larger — about 2.4× Novavax Inc's market cap, and WD 40 Company pays a 1.75% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | WDFC | |
|---|---|---|
Market Cap | $1.31B | $3.13B |
Sector | Health | Technology |
52-Week High | $11.19 | $264.91 |
52-Week Low | $6.22 | $187.52 |
Enterprise Value | $889.30M | $3.18B |
Dividend Yield | — | 1.75% |
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
WDFC trades at $232.3, down 0.94% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, but faces gross margin pressure from input costs. Revenue grew to $675 million in 2026, though net income slightly declined to $89 million. A dividend of $1.02 per share is scheduled for payment on July 31, 2026.
The outlook is mixed: solid brand strength and cash flow support stability, but high valuation (P/E 35.39) and margin pressures pose risks. Analyst sentiment is cautious with a hold-heavy consensus. Key opportunities include global market penetration, while risks involve cost inflation and competitive pressures.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →